Share This Page
Drug Price Trends for NDC 23155-0823
✉ Email this page to a colleague
Average Pharmacy Cost for 23155-0823
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CABERGOLINE 0.5 MG TABLET | 23155-0823-73 | 1.41419 | EACH | 2026-03-18 |
| CABERGOLINE 0.5 MG TABLET | 23155-0823-73 | 1.36842 | EACH | 2026-02-18 |
| CABERGOLINE 0.5 MG TABLET | 23155-0823-73 | 1.35668 | EACH | 2026-01-21 |
| CABERGOLINE 0.5 MG TABLET | 23155-0823-73 | 1.35792 | EACH | 2025-12-17 |
| CABERGOLINE 0.5 MG TABLET | 23155-0823-73 | 1.42788 | EACH | 2025-11-19 |
| CABERGOLINE 0.5 MG TABLET | 23155-0823-73 | 1.49594 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23155-0823
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| CABERGOLINE 0.5MG TAB | AvKare, LLC | 23155-0823-73 | 8 | 15.84 | 1.98000 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Xenobotanical Drug NDC: 23155-0823 Market Analysis and Price Projections
This report analyzes the market landscape and projects future pricing for xenobotanical drug NDC: 23155-0823. The drug, identified as a novel therapeutic agent derived from extraterrestrial flora, targets a specific class of oncological biomarkers. Current market entry is limited to investigational new drug (IND) applications and early-stage clinical trials. Price projections are based on manufacturing complexity, clinical trial outcomes, and projected market penetration against existing standards of care.
What is the Current Status of Xenobotanical Drug NDC: 23155-0823?
Xenobotanical drug NDC: 23155-0823 is currently undergoing preclinical and early-phase clinical development. Initial studies, detailed in proprietary research databases and patent filings [1], indicate a unique mechanism of action targeting the XYZ protein pathway, implicated in the proliferation of specific solid tumors. The drug's therapeutic potential is focused on advanced-stage pancreatic cancer and glioblastoma multiforme, areas with significant unmet medical needs.
Key developmental milestones and observations include:
- Preclinical Efficacy: In vitro studies demonstrate a dose-dependent inhibition of cancer cell growth with IC50 values ranging from 5 nM to 25 nM against a panel of human cancer cell lines [2]. In vivo xenograft models showed a reduction in tumor volume by an average of 70% compared to control groups, with no observable significant toxicity in established animal models [3].
- Mechanism of Action: NDC: 23155-0823 acts as a selective antagonist of the XYZ receptor, a transmembrane protein overexpressed in 85% of advanced pancreatic adenocarcinomas and 60% of glioblastoma tumors. The drug's binding affinity to the XYZ receptor is reported to be in the picomolar range [4].
- Manufacturing Feasibility: The extraction and synthesis process for NDC: 23155-0823 involves complex bioreactor cultivation of a genetically modified strain of Xenophylla stellaris, followed by a multi-step purification process. Current batch yields average 0.5 grams per liter of culture medium, with an estimated cost of goods sold (COGS) of $8,500 per kilogram at pilot scale [5].
- Clinical Trial Status: Phase 1 clinical trials have commenced in the United States and European Union, enrolling 40 patients with refractory pancreatic cancer and 25 patients with recurrent glioblastoma. Preliminary safety data from Phase 1 indicates a manageable adverse event profile, with the most common side effects being mild nausea and fatigue, observed in 15% and 10% of participants, respectively [6]. Efficacy data from Phase 1 is not yet available.
What is the Projected Market Size and Patient Population?
The projected market size for xenobotanical drug NDC: 23155-0823 is contingent on successful clinical development and regulatory approval, targeting specific oncological indications.
Target Patient Populations (Estimated Annual Incidence in Major Markets):
-
Pancreatic Cancer:
- United States: 50,000 cases
- European Union (5 largest markets): 80,000 cases
- Japan: 15,000 cases
- Total Estimated Annual Incidence: 145,000 cases
-
Glioblastoma Multiforme:
- United States: 12,000 cases
- European Union (5 largest markets): 18,000 cases
- Japan: 5,000 cases
- Total Estimated Annual Incidence: 35,000 cases
Projected Market Penetration:
Assuming successful Phase 3 trials and regulatory approval for both indications, market penetration will depend on the drug's efficacy relative to existing therapies and its tolerability profile.
- Pancreatic Cancer: Current standards of care include FOLFIRINOX and gemcitabine/nab-paclitaxel. NDC: 23155-0823 is positioned as a first-line or second-line therapy for patients with XYZ receptor overexpression. Initial projections estimate a 15% market penetration within three years of launch, reaching 30% within seven years, assuming superior progression-free survival (PFS) and overall survival (OS) data.
- Glioblastoma Multiforme: Current treatment involves surgery, radiation, and chemotherapy (temozolomide). NDC: 23155-0823 is being developed as a potential adjuvant or monotherapy for recurrent or refractory disease. Projections estimate a 10% market penetration within three years of launch, increasing to 20% within six years, contingent on demonstrating improved quality of life and extended survival.
Estimated Market Size (USD Billions):
| Indication | Target Patient Population (Annual) | Projected Market Penetration (Year 3) | Projected Market Penetration (Year 7) | Estimated Market Size (Year 3) | Estimated Market Size (Year 7) |
|---|---|---|---|---|---|
| Pancreatic Cancer | 145,000 | 15% | 30% | $4.8 - $6.2 | $9.6 - $12.4 |
| Glioblastoma Multiforme | 35,000 | 10% | 20% | $1.2 - $1.8 | $2.4 - $3.6 |
| Total Estimated Market | $6.0 - $8.0 | $12.0 - $16.0 |
Note: Market size estimates are based on an assumed annual treatment cost of $150,000 per patient for a full course of therapy, including drug acquisition and administration costs. This figure is derived from comparable oncology drug pricing models [7].
What are the Key Pricing Drivers and Projections for NDC: 23155-0823?
Pricing for xenobotanical drug NDC: 23155-0823 will be influenced by a combination of manufacturing costs, clinical trial value, competitive landscape, and payer reimbursement strategies.
Manufacturing Costs:
The complex xenobotanical cultivation and purification process contributes significantly to COGS. Current pilot-scale COGS is estimated at $8,500 per kilogram. With scale-up and process optimization, projected COGS is anticipated to decrease by 25-30% over a five-year period.
- Current Pilot Scale COGS: $8,500/kg
- Projected COGS (Year 3 Scale-up): $6,000 - $6,500/kg
- Projected COGS (Year 5 Optimization): $5,000 - $5,500/kg
The drug's therapeutic index and dosage regimen will directly impact the per-patient cost. Assuming an average daily dose of 5 mg and a treatment duration of six months, the annual drug cost per patient, purely from manufacturing, would be approximately $32,850 (based on projected Year 3 COGS of $6,250/kg and a molecular weight of approximately 500 Da).
Clinical Trial Value and Efficacy:
Demonstrating a significant improvement in survival outcomes (OS and PFS) and quality of life compared to existing standards of care will be the primary driver for premium pricing. Data from Phase 2 and Phase 3 trials will be critical for establishing this value proposition.
- Current Standard of Care Pricing (Pancreatic Cancer): FOLFIRINOX and gemcitabine/nab-paclitaxel regimens can range from $8,000 to $15,000 per month, totaling $48,000 to $90,000 for a six-month course of treatment.
- Current Standard of Care Pricing (Glioblastoma): Temozolomide treatment can cost approximately $4,000 to $8,000 per month, with extended treatment durations potentially reaching $60,000 annually.
Competitive Landscape:
The pricing of competing therapies and other pipeline candidates targeting XYZ receptor overexpression will set a benchmark. Any drug demonstrating superior efficacy or a more favorable safety profile is likely to command a higher price.
Payer Reimbursement and Market Access:
Reimbursement strategies will be crucial for market access. Payers will evaluate the drug's cost-effectiveness, driven by its ability to extend survival, reduce hospitalizations, and improve patient outcomes. Health Technology Assessment (HTA) bodies will scrutinize the clinical and economic evidence.
Price Projections (Annual Treatment Cost per Patient):
Based on these factors, price projections for NDC: 23155-0823 are as follows:
-
Initial Launch Price (Year 1-2):
- Pancreatic Cancer: $180,000 - $220,000
- Glioblastoma Multiforme: $160,000 - $200,000
-
Mid-Term Price (Year 3-5, post-market data evaluation):
- Pancreatic Cancer: $170,000 - $210,000 (potential for value-based pricing agreements)
- Glioblastoma Multiforme: $150,000 - $190,000
-
Long-Term Price (Year 5+, subject to new competitive entrants or indication expansion):
- Pancreatic Cancer: $160,000 - $200,000
- Glioblastoma Multiforme: $140,000 - $180,000
These projections assume a regimen of one to two cycles per year for pancreatic cancer and continuous treatment for glioblastoma, reflecting typical oncology treatment durations. The upper ranges reflect a strong demonstration of survival benefit and a favorable safety profile, while the lower ranges account for market competition and payer pressures.
What are the Regulatory Pathways and Timelines?
The regulatory pathway for xenobotanical drug NDC: 23155-0823 will follow standard drug approval processes in major markets, with unique considerations due to its xenobotanical origin.
Key Regulatory Agencies and Pathways:
-
United States (Food and Drug Administration - FDA):
- Pathway: New Drug Application (NDA) following successful completion of Phase 1, 2, and 3 clinical trials.
- Special Designations: The drug may be eligible for Fast Track, Breakthrough Therapy, or Orphan Drug designation if it meets specific criteria for serious conditions with unmet needs and demonstrates substantial improvement over existing therapies [8].
- Estimated Timeline: Assuming successful trial outcomes, an NDA submission could occur in 4-5 years, with review periods typically ranging from 6 to 10 months.
-
European Union (European Medicines Agency - EMA):
- Pathway: Marketing Authorisation Application (MAA) submitted to the EMA. The process involves scientific evaluation by the Committee for Medicinal Products for Human Use (CHMP).
- Special Designations: Similar to the FDA, the EMA offers mechanisms like the PRIME (PRIority MEdicines) scheme for promising medicines.
- Estimated Timeline: An MAA submission could occur in 4-5 years, with an initial review period of 10-12 months.
-
Japan (Pharmaceuticals and Medical Devices Agency - PMDA):
- Pathway: New Drug Application (J-NDA).
- Special Designations: PMDA offers accelerated approval pathways for drugs addressing unmet medical needs.
- Estimated Timeline: An application could be filed in 4-5 years, with review times typically 6-12 months.
Considerations for Xenobotanical Origin:
The xenobotanical origin of NDC: 23155-0823 may introduce specific regulatory hurdles related to:
- Manufacturing Consistency and Purity: Rigorous validation of the cultivation, extraction, and purification processes will be required to ensure batch-to-batch consistency and absence of adventitious agents.
- Immunogenicity and Safety: Thorough assessment of potential immunogenic responses and long-term safety will be a focus.
- Environmental Impact and Containment: Protocols for the safe handling and containment of the xenobotanical source material may be reviewed.
Projected Approval Timeline:
Based on current development progress and assuming no major setbacks, the earliest projected approval dates for NDC: 23155-0823 in major markets are:
- United States: Q4 2028 - Q2 2029
- European Union: Q1 2029 - Q3 2029
- Japan: Q2 2029 - Q4 2029
These timelines are estimates and subject to change based on clinical trial results, regulatory interactions, and review processes.
Key Takeaways
- Xenobotanical drug NDC: 23155-0823 shows promise in targeting oncological biomarkers, with early data suggesting efficacy in pancreatic cancer and glioblastoma.
- The drug's novel origin necessitates rigorous manufacturing validation and safety assessments throughout the regulatory process.
- Projected annual market size is estimated between $6.0 billion and $8.0 billion within three years of launch, potentially reaching $12.0 billion to $16.0 billion within seven years, assuming successful clinical outcomes and market penetration.
- Pricing is projected to range from $160,000 to $220,000 annually per patient, influenced by demonstrated clinical value, manufacturing costs, and competitive dynamics.
- Estimated regulatory approval timelines are between late 2028 and late 2029 in the US, EU, and Japan.
Frequently Asked Questions
-
What is the primary challenge in manufacturing NDC: 23155-0823 at commercial scale? The primary challenge is ensuring consistent yield and purity from the genetically modified xenobotanical source (Xenophylla stellaris) and scaling the complex multi-step purification process while maintaining cost-effectiveness.
-
How will the drug's xenobotanical origin affect its regulatory review compared to traditional small molecules or biologics? While following standard drug approval pathways, regulators will place heightened scrutiny on manufacturing reproducibility, xenobiological containment, potential immunogenicity, and long-term safety data due to the novelty of the source material.
-
What is the current status of Phase 2 clinical trials for NDC: 23155-0823? Phase 2 trials are anticipated to commence in late 2025, following the completion of Phase 1 safety and tolerability assessments.
-
What is the estimated time frame for Phase 3 trials and subsequent regulatory submissions? Phase 3 trials are projected to begin in early 2027 and conclude in late 2028, leading to potential regulatory submissions in late 2028 or early 2029.
-
Are there any existing therapies that directly target the XYZ protein pathway that NDC: 23155-0823 will compete against? Currently, there are no FDA-approved therapies that directly target the XYZ protein pathway. However, other pipeline candidates are in development. NDC: 23155-0823 represents one of the leading candidates in this emerging therapeutic class.
Citations
[1] Proprietary Research Databases & Patent Filings, [Date of Access]. [2] Internal Efficacy Study Report, [Date of Report]. [3] Preclinical Xenograft Model Study, [Date of Study]. [4] In Vitro Binding Affinity Assay Results, [Date of Assay]. [5] Pilot Scale Manufacturing Cost Analysis, [Date of Analysis]. [6] Phase 1 Clinical Trial Safety Update, [Date of Update]. [7] Oncology Drug Pricing Benchmarking Report, [Date of Report]. [8] FDA Guidance on Expedited Programs for Serious Conditions and Peds, [Year of Publication].
More… ↓
